Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is hosting an exclusive live investor webinar and Q&A session on October 17, 2024, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature Nutriband Founder and CEO Gareth Sheridan and Founder and President Serguei Melnik, who will discuss the company's current operations and upcoming milestones.
Nutriband is addressing the global opioid crisis with its AVERSA™ abuse-deterrent transdermal technology. The company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million upon FDA approval. Nutriband is pursuing a streamlined 505(b)(2) NDA regulatory pathway, requiring only a single Phase 1 trial with potential for an expedited six-month FDA review.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), sviluppatore di soluzioni farmaceutiche transdermiche, ospiterà un esclusivo webinar per investitori dal vivo e una sessione di domande e risposte il 17 ottobre 2024, alle 16:15 ET. L'evento, organizzato da RedChip Companies, vedrà la partecipazione di Gareth Sheridan, Fondatore e CEO di Nutriband e Serguei Melnik, Fondatore e Presidente, i quali discuteranno delle operazioni attuali dell'azienda e dei prossimi traguardi.
Nutriband sta affrontando la crisi globale degli oppioidi con la sua tecnologia transdermica deterrente all'abuso AVERSA™. Il prodotto di punta dell'azienda, AVERSA™ Fentanyl, punta a vendite annuali di picco di 80 milioni a 200 milioni di dollari all'approvazione della FDA. Nutriband sta perseguendo un percorso normativo semplificato per la NDA 505(b)(2), che richiede solo un singolo trial di Fase 1 con potenziale per una revisione accelerata della FDA di sei mesi.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), un desarrollador de soluciones farmacéuticas transdérmicas, está organizando un exclusivo seminario web en vivo para inversores y una sesión de preguntas y respuestas el 17 de octubre de 2024, a las 16:15 ET. El evento, presentado por RedChip Companies, contará con la participación de Gareth Sheridan, Fundador y CEO de Nutriband y Serguei Melnik, Fundador y Presidente, quienes discutirán las operaciones actuales de la empresa y los próximos hitos.
Nutriband está abordando la crisis global de los opioides con su tecnología transdérmica de disuasión de abuso AVERSA™. El producto principal de la empresa, AVERSA™ Fentanilo, tiene como objetivo alcanzar ventas anuales máximas de 80 millones a 200 millones de dólares tras la aprobación de la FDA. Nutriband está siguiendo un camino regulatorio NDA 505(b)(2) simplificado, que solo requiere un único ensayo de Fase 1 con potencial para una revisión acelerada de la FDA de seis meses.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), 경피 약물 솔루션 개발업체는 2024년 10월 17일 오후 4시 15분 ET에 독점적인 라이브 투자자 웨비나 및 Q&A 세션을 개최합니다. RedChip Companies가 주최하는 이번 행사에는 Nutriband의 창립자이자 CEO인 Gareth Sheridan와 설립자이자 회장인 Serguei Melnik이 참석하여 회사의 현재 운영 및 다가오는 이정표에 대해 논의합니다.
Nutriband는 AVERSA™ 남용 억제 경피 기술을 통해 전 세계적인 오피오이드 위기에 대응하고 있습니다. 회사의 주요 제품인 AVERSA™ 펜타닐은 FDA 승인 시 8천만 달러에서 2억 달러의 연간 판매 정점을 목표로 하고 있습니다. Nutriband는 단일 1상 시험만 필요한 간소화된 505(b)(2) NDA 규제 경로를 취하고 있으며, 이를 통해 최대 6개월의 신속한 FDA 검토가 가능합니다.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), un développeur de solutions pharmaceutiques transdermiques, organise un webinaire exclusif en direct pour investisseurs et une session de questions-réponses le 17 octobre 2024 à 16h15 ET. L'événement, animé par RedChip Companies, mettra en vedette Gareth Sheridan, Fondateur et CEO de Nutriband et Serguei Melnik, Fondateur et Président, qui discuteront des opérations actuelles de l'entreprise et des prochaines étapes importantes.
Nutriband aborde la crise mondiale des opioïdes avec sa technologie transdermique de résistance à l'abus AVERSA™. Le produit phare de l'entreprise, AVERSA™ Fentanyl, vise des ventes annuelles de pic de 80 millions à 200 millions de dollars après l'approbation de la FDA. Nutriband suit une voie réglementaire NDA 505(b)(2) simplifiée, nécessitant uniquement un essai de phase 1 avec le potentiel d'un examen accéléré par la FDA de six mois.
Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), ein Entwickler transdermaler pharmazeutischer Lösungen, veranstaltet am 17. Oktober 2024 um 16:15 Uhr ET ein exklusives Live-Webinar für Investoren sowie eine Frage- und Antwortsitzung. Die Veranstaltung, die von RedChip Companies ausgerichtet wird, zeigt Gareth Sheridan, Gründer und CEO von Nutriband, sowie Serguei Melnik, Gründer und Präsident, die über die aktuellen Geschäfte des Unternehmens und bevorstehende Meilensteine sprechen werden.
Nutriband geht die globale Opioidkrise mit seiner AVERSA™ missbrauchsverhindernden transdermalen Technologie an. Das führende Produkt des Unternehmens, AVERSA™ Fentanyl, strebt nach der Genehmigung durch die FDA ein jährliches Verkaufsvolumen von 80 Millionen bis 200 Millionen Dollar an. Nutriband verfolgt einen vereinfachten NDA-Regulierungsweg nach 505(b)(2), der nur eine einzige Phase-1-Studie erfordert und das Potenzial für eine beschleunigte FDA-Prüfung von sechs Monaten bietet.
- AVERSA™ Fentanyl targeting peak annual sales of $80 million to $200 million upon FDA approval
- Streamlined 505(b)(2) NDA regulatory pathway requiring only a single Phase 1 trial
- Potential for expedited six-month FDA review, accelerating path to market
- None.
ORLANDO, FL / ACCESSWIRE / October 2, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, is pleased to invite investors to a webinar on October 17, 2024, at 4:15 p.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Nutriband Founder and Chief Executive Officer Gareth Sheridan and Founder and President Serguei Melnik, who will share insight into the Company's current operations and upcoming milestones. Nutriband stands at the forefront of addressing the global opioid crisis with its revolutionary AVERSA™ abuse-deterrent transdermal technology. The Company's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_puDtTn88Rg2xBWZqLE7MkA#/registration
Questions can be pre-submitted to NTRB@redchip.com or online during the live event.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024, filed May 1, 2023, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
NTRB@redchip.com
SOURCE: Nutriband, Inc.
View the original press release on accesswire.com
FAQ
When is Nutriband Inc. (NTRB) hosting its live investor webinar?
What is the potential peak annual sales target for Nutriband's AVERSA™ Fentanyl?
What regulatory pathway is Nutriband (NTRB) pursuing for AVERSA™ Fentanyl?
How is Nutriband (NTRB) addressing the global opioid crisis?
